Highlights Mabpharm Limited

Equities

2181

KYG5780F1046

Delayed Hong Kong S.E. Other stock markets 11:29:35 2024-05-01 pm EDT			5-day change	1st Jan Change
0.365 ^HKD	-8.75%		-14.12%	-20.65%

Mar. 26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 10	Livzon Pharma Recognizes Credit, Asset Impairments	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Livzon Pharma Recognizes Credit, Asset Impairments	Jan. 10	MT
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	Dec. 04	MT
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Mabpharm Grants Jemincare Pharma Unit Promotion Rights to Asthma Drug	23-04-13	MT
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Chinese Regulator Accepts Mabpharm's New Drug Application for Colorectal Cancer Treatment	23-03-14	MT
Mabpharm Limited Announces New Drug Application of CMAB009	23-03-14	CI
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
China Approves Clinical Trials for Mabpharm's Psoriasis Treatment	22-07-28	MT
Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis	22-07-27	CI
Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017	22-07-05	CI
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-25	CI
Chinese Regulators OK Mabpharm's Clinical Trial Application for Tumor Bone Metastasis Treatment	22-01-13	MT
Mabpharm Limited Announces Approval of Clinical Trial Application of CMAB807X by the National Medical Products Administration of China	22-01-13	CI
Mabpharm Limited Announces Acceptance of the New Drug Application of Core Product CMAB007 by the National Medical Products Administration	21-10-15	CI
Livzon Pharmaceutical : Pharma's Assisted Reproductive Drug Wins Clinical Trial Approval in China	21-09-13	MT
Mabpharm Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2021	21-08-27	CI
Sorrento Therapeutics' : Partner Secures China's Marketing Approval For Infliximab Biobetter	21-07-20	MT
Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter	21-07-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mabpharm Limited

Equities

2181

KYG5780F1046

Highlights

Filters